Document is current
Any future updates will be listed below
-
Authors
Nakashima, Kazuhisa
Yokomizo, Ayako
Murakami, Michiyasu
Okita, Kenji
Wada, Makoto
Iino, Keiko
Akechi, Tatsuo
Iihara, Hirotoshi
Imamura, Chiyo K.
Okuyama, Ayako
Ozawa, Keiko
Kim, Yong-il
Sasaki, Hidenori
Satomi, Eriko
Takeda, Masayuki
Tanaka, Ryuhei
Nakajima, Takako Eguchi
Nakamura, Naoki
Nishimura, Junichi
Noda, Mayumi
Hayashi, Kazumi
Higashi, Takahiro
Boku, Narikazu
Matsumoto, Koji
Matsumoto, Yoko
Yamamoto, Nobuyuki
Aogi, Kenjiro
Abe, Masakazu
-
Funding
Funding for this research was provided by:
Japan Society of Clinical Oncology
- License Information
-
More Information
Article History
Received: 1 August 2024
Accepted: 5 October 2024
First Online: 17 October 2024
Declarations
:
: Kazuhisa Nakashima received honoraria from Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., AstraZeneca K.K., and Eli Lilly Japan K.K. Michiyasu Murakami received honoraria from Taiho Pharmaceutical Co., Ltd. Eriko Satomi received honoraria from Shionogi & Co., Ltd. Masayuki Takeda received honoraria from Chugai Pharmaceutical Co., Ltd., AstraZeneca K.K., Novartis Pharma K.K., Ono Pharmaceutical Co., Ltd., and Bayer. Takako Eguchi Nakajima received research funding from KBBM, Inc. and Takeda Pharmaceutical Co., Ltd. Junichi Nishimura received honoraria from Taiho Pharmaceutical Co., Ltd. Narikazu Boku received honoraria from Ono Pharmaceutical Co., Ltd., Bristol Myers Squibb, Daiichi Sankyo Co., Ltd., Taiho Pharmaceutical Co., Ltd., and Eli Lilly Japan K.K. Koji Matsumoto received honoraria from MSD K.K., Kyowa Kirin Co., Ltd., and Chugai Pharmaceutical Co., Ltd. as well as research funding from Daiichi Sankyo Co., Ltd., MSD K.K., Gilead Sciences, Inc., and Eli Lilly Japan K.K. Nobuyuki Yamamoto received honoraria from MSD K.K., Accuray Japan K.K., AstraZeneca K.K., Abbvie Inc., Amgen Inc., Ono Pharmaceutical Co., Ltd., Guardant Health Japan Corp., Daiichi Sankyo Co., Ltd., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Chugai Foundation for Innovative Drug Discovery Science, Lao Tsumura Co., Ltd., Terumo Corporation, Eli Lilly Japan K.K., Nippon Kayaku Co., Ltd., Novartis AG, Pfzer Global Supply Japan Inc., Merck Biopharma Co., Ltd, Pfzer Global Supply Japan Inc., Merck Biopharma Co., Ltd., Janssen Pharmaceutical K.K., and USACO Corporation, as well as legal fees in case of lawsuit from Taiho Pharmaceutical Co., Ltd., Boehringer Ingelheim Japan, Chugai Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Nippon Kayaku Co., Ltd., Prime Research Institute for Medical RWD, Inc., AstraZeneca K.K., and A2 Healthcare Corporation. Other authors declare that they have no conflict of interest.
: Not applicable.
: Formal consent was not required for this type of study.
: Not applicable.
: All authors consented to the publication of this study.
